CC-90011 (Celgene/Bristol Myers Squibb (BMS)) selective, reversible LSD1 inhibitor clinical candidate)
< 1 minute read
Sep. 18, 2021
CC-90011: A Selective and Reversible LSD1 Inhibitor
CC-90011
selective, reversible LSD1 inhibitor <100 mg orally QW, in Ph. II for 1L ES-SCLC from 300k+ cmpd HTS, SBDD + opt. J. Med. Chem., Oct. 9, 2020 Celgene/Bristol Myers Squibb, San Diego, CA
Loading...
